Thiery JP, Sleeman JP: Complex networks orchestrate epithelial -mesenchymal transitions. Nat Rev Mol Cell Biol 7:131 -42, 2006 13. Kalluri R, Weinberg RA: The basics of epithelial -mesenchymal transition. J Clin Invest 119:1420-8, 2009 14. Gravdal K, Halvorsen OJ, Haukaas SA, et al: A switch from E-cadherin to N- cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 13:7003-11, 2007 15. Onder TT, Gupta PB, Mani SA, et al: Loss of E- cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68:3645-54, 2008 16. Yang J, Mani SA, Donaher JL, et al: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927 -39, 2004 17. Fernando RI, Litzinger M, Trono P, et al: The T-box transcription factor Brachyury promotes epithelial- mesenchymal transition in human tumor cells. J Clin Invest 120:533-44, 2010 57 Abbreviated Title: Phase I MVA -Brachyury -TRICOM Version Date: September 14, 2016 Confidential 18. Roselli M, Fernando RI, Guadagni F, et al: Brachyury, a driver of the epithelial- mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res 18:3868-79, 2012 19. Palena C, Roselli M, Litzinger M, et al: Brachyury, an EMT Driver, Is Overexpressed in Breast Carcinomas and Associates with Poor Prognosis. Submitted to JNCI with 2nd revisions, Nov 2013 20. Hamilton DH, Litzinger MT, Fernando RI, et al: Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal -like phenotype of carcinomas. Semin Oncol 39:358-66, 2012 21. Madan RA, Mohebtash M, Arlen PM, et al: Ipilimumab and a poxviral vaccine targeting prostate -specific antigen in metastatic castration -resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 13:501-8, 2012 22. Morrissey PJ, Bressler L, Park LS, et al: Granulocyte- macrophage colony - stimulating factor augments the primary antibody response by enhancing the function of antigen- presenting cells. J Immunol 139:1113-9, 1987 23. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete murine granu locyte -macrophage colony- stimulating factor stimulates potent, specific, and long- lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90:3539-43, 1993 24.